Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- MOF Demands \220 Bil. Cut in Social Security Spending Again in FY2008
August 27, 2007
- Chuikyo to Show Road Map for Revisions of Medical Fees in April 2008
August 27, 2007
- SEMINAR
August 27, 2007
- Korosho Starts Studies for Mutual Acceptance of Clinical Data from Japan, Korea, China
August 27, 2007
- DSP to Independently Market Lurasidone in US
August 27, 2007
- Indonesia Again Suspends Supply of Influenza Virus Samples: WHO
August 27, 2007
- GSK and Takeda to Provide "Boxed" Warning on Avandia and Actos
August 27, 2007
- UK High Court Orders NICE to Amend Guidance for Alzheimer's Disease
August 27, 2007
- Novartis Concerned about Indian Patent Law - Patent Application for Glivec Rejected
August 27, 2007
- Takeda Files MAA for Idebenone in EU
August 27, 2007
- REGULATORY NEWS IN BRIEF
August 27, 2007
- Vice Health Minister Unofficially Meets JGPMA Leaders to Promote Use of Generics
August 27, 2007
- Antidepressant Medication Altered by 40% of Patients: GSK
August 27, 2007
- 47 Programs in PII Trials: Pfizer
August 27, 2007
- Takeda, Santhera Extend Marketing Collaboration in EU for SNT-MC17
August 20, 2007
- Astellas Reorganizes European Business Functions
August 20, 2007
- REGULATORY NEWS IN BRIEF(1)
August 20, 2007
- Chugai: Half-Year Sales Up 12%, Ordinary Profits Up 30.5%
August 20, 2007
- REGULATORY NEWS IN BRIEF(2)
August 20, 2007
- Takeda, Taiyo in Dispute over Recall of Pansporin
August 20, 2007
ページ
Japan will overhaul its R&D tax credit regime in its FY2026 reform, introducing a new strategic category alongside existing frameworks.…
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…